FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma

Go back to FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma
Roche Holding AG Basel American Depositary Shares (AMEX: RHHBY) Delayed: 53.93 +2.23 (4.31%)
Previous Close $51.70    52 Week High $35.13 
Open $52.10    52 Week Low $28.10 
Day High $53.97    P/E N/A 
Day Low $51.99    EPS $0.00 
Volume 2,075,410       

Brown & Brown, Inc. (NYSE: RO) Delayed: 8.49 +0.55 (6.93%)
Previous Close $7.94    52 Week High $8.59 
Open $7.94    52 Week Low $7.82 
Day High $8.59    P/E 6.53 
Day Low $7.82    EPS $1.30 
Volume 42,732       

Roper Industries (NASDAQ: ROP) Delayed: 360.73 +24.02 (7.13%)
Previous Close $336.71    52 Week High $195.93 
Open $365.74    52 Week Low $155.79 
Day High $369.15    P/E 67.18 
Day Low $355.02    EPS $5.37 
Volume 804,902